Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alfasigma S.p.A.
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
- Other Names / Subsidiaries
- Defiante Farmaceutica S.A.
- Sigma-Tau Pharma Ltd
- Sigma-Tau Arzneimittel GmbH
- Sigma-Tau Research Switzerland SA
- Biofutura Pharma S.p.A.
- Alfa Wassermann SpA